CAR T Research and Treatment Advances in Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Follicular Cell Lymphoma (FL) Therapies

CAR T Research and Treatment Advances in Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Follicular Cell Lymphoma (FL) Therapies is organized by AcademicCME.

Program Dates: Mar 27, 2024 - Mar 26, 2025

Description:
This CME program will highlight recent advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and follicular cell lymphoma (FL). The expert faculty, led by Jeremy S. Abramson, MD, will first provide an update on CAR T cell therapies in 2024, including a summary of current approvals in the lymphoma treatment landscape. Following, recent trial data, including patient selection and sequencing, for CLL, MCL and FL therapeutics will be reviewed, along with the implications for clinical practice. The expert faculty will conclude with a case-based discussion of best practices for the treatment and management of patients with lymphomas to improve outcomes and quality of life.

Learning Objectives:

• Healthcare providers should review and be able to analyze and contextualize clinical trial data for CAR T cell therapy to manage patients with CLL, FL and MCL released at ASCO 2023, ICML 2023, and ASH 2023
• Healthcare providers should be able to choose and position CAR T cell therapy to treat CLL, guided by clinical trial findings optimizing mechanism of action, sequencing of therapy, and patient selection
• Healthcare providers should review and be able to analyze and contextualize clinical trial data for CAR T cell therapy to manage patients with mantle cell lymphoma, including data released at ICML 2023 and ASH 2023
• Healthcare providers should review and be able to analyze and contextualize clinical trial data for CAR T cell therapy to manage patients with follicular cell lymphoma, including data released at ICML 2023 and ASH 2023
• Healthcare providers in varied practice settings should have the opportunity to critically evaluate and consider incorporation of practice patterns from outside their experience in the management of patients with lymphomas.